Partnerships and licensing agreements are the primary mechanism through which biotechnology platform technologies reach patients — Regeneron's Dupixent partnership with Sanofi, Alnylam's inclisiran partnership with Novartis, and Vertex's CASGEVY co-development with CRISPR Therapeutics are the defining commercial partnerships of the modern biotechnology industry. The economics of biotech partnering — upfront payments, milestone structures, royalty rates, and co-commercialization arrangements — reflect the risk-sharing imperative of drug development and the value of validated platform technologies.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Table of Contents
1. Executive Summary
2. Overview
3. Platform Technology Deals
4. Co-Development Partnerships
5. Licensing Economics
6. Academic Collaborations
7. Cross-Industry Partnerships
8. Deal Structure Trends
9. Due Diligence
10. Strategic Recommendations
11. Competitive Landscape
12. Strategic Conclusions
13. Appendix
List of Tables
Table 1. Overview and Key Data 2025
Table 2-8. Topic-Specific Analysis Tables
Table 2. Leading Companies — Strategy Assessment 2025
Table 3. Key Risks and Mitigation Strategies
Companies Profiled
Regeneron
Vertex
CRISPR Therapeutics
Sanofi
